AzTrials
AzTrials

Type 2 Diabetes (T2D)Phase 2NCT06542874

A Research Study Comparing How Well Different Doses of the Medicine NNC0487-0111 Lower Blood Sugar in People With Type 2 Diabetes

A Phase 2 study testing NNC0487-0111 subcutanous and NNC0487-0111 oral in people with Type 2 Diabetes (T2D), run by Novo Nordisk A/S at 137 sites in 11 countries.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

The study will look at how well different doses of a new medicine called NNC0487-0111 help lower the blood sugar and body weight in people with type 2 diabetes. NNC0487-0111 is a new medicine which cannot be prescribed by doctors but has previously been tested in humans. Read more about this study

Who is it for?
Ages 18 to 75 years
Conditions the study is for
Type 2 Diabetes (T2D)
What is being tested?
NNC0487-0111 subcutanous and NNC0487-0111 oral
Could I receive a placebo?
Yes, some participants may receive a placebo
How many people
448 participants
Where
137 sitesin 11 countries
Study dates
7 Aug 2024to 24 Oct 2025
Phase
Phase 2
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 to 75 years
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • Male or female, aged 18-75 years (both inclusive) at the time of signing the informed consent.
  • Diagnosed with type 2 diabetes mellitus greater or equal to 180 days before screening.
  • Stable daily dose(s) greater or equal to 90 days before screening of the following antidiabetic drug(s) or combination regimen(s) at effective or maximum tolerated dose as judged by the investigator: metformin with or without SGLT2 inhibitor.
  • HbA1c of 7.0-10.0 procent (53-86 mmol/mol) (both inclusive) as assessed by central laboratory at screening.
  • Body mass index between greater or equal to 23.0 and below 50.0 kg/m^2.
  • Able and willing to adhere to the protocol including wearing a continuous glucose monitoring (CGM) device provided for the study, as judged by the investigator.

Who cannot join

  • Treatment with any medication for the indication of diabetes or obesity other than stated in the inclusion criteria within 90 days before screening. However, short term insulin treatment for a maximum of 14 consecutive days and prior insulin treatment for gestational diabetes are allowed.
  • Uncontrolled and potentially unstable diabetic retinopathy or maculopathy. Verified by a fundus examination performed within 90 days before screening or in the period between screening and randomisation. Pharmacological pupil-dilation is a requirement unless using a digital fundus photography camera specified for non-dilated examination.
  • Known hypoglycaemic unawareness as indicated by the investigator according to Clarke's questionnaire question.

Trial locations and contacts

137 sites in 11 countries.

137 sites in 11 countries

United States39 sites

  • AMC Community Endocrinology

    Albany, New York, 12203

  • Uni of Alabama at Birmingham

    Birmingham, Alabama, 35294

  • Brigham & Women's Hospital

    Boston, Massachusetts, 02115

  • Clinical Research Professionals

    Chesterfield, Missouri, 63005

  • Cedar-Crosse Research Center

    Chicago, Illinois, 60607

  • StudyMetrix Research LLC

    City of Saint Peters, Missouri, 63303

  • Velocity Clinical Res-Dallas

    Dallas, Texas, 75230

  • Lillestol Research LLC

    Fargo, North Dakota, 58104

  • Plains Clinical Research Center, LLC_Fargo

    Fargo, North Dakota, 58104

  • Fleming Island Ctr for Clin Res

    Fleming Island, Florida, 32003

  • Encore Medical Research LLC

    Hollywood, Florida, 33024

  • Victorium Clinical Research

    Houston, Texas, 77024

  • Synergy Groups Medical

    Houston, Texas, 77061

  • PlanIt Research, PLLC

    Houston, Texas, 77079

  • Medstar Research Institute_Hyattsville

    Hyattsville, Maryland, 20782

  • Holston Medical Group

    Kingsport, Tennessee, 37660

  • Radiance Clinical Research

    Lampasas, Texas, 76550

  • Velocity Clin Research LA

    Los Angeles, California, 90057

  • Tekton Research

    McKinney, Texas, 75069

  • ActivMed Practice & Research LLC

    Methuen, Massachusetts, 01844

  • South Broward Research LLC

    Miramar, Florida, 33027

  • Centricity Rsrch MHCity Multi

    Morehead City, North Carolina, 28557

  • Clinical Research Associates

    Nashville, Tennessee, 37203

  • MidState Endocrine Associates

    Nashville, Tennessee, 37203

  • Alliance for Multispec Res

    Norman, Oklahoma, 73069

  • Florida Inst For Clin Res

    Orlando, Florida, 32825

  • Florida Institute for Clinical research

    Orlando, Florida, 32825

  • MD Medical Research

    Oxon Hill, Maryland, 20745

  • Advanced Internal Medicine, PLLC

    Paducah, Kentucky, 42001

  • Jefferson Endocrinology Assocs

    Philadelphia, Pennsylvania, 19107-6810

  • Preferred Primary Care Physicians_Pittsburgh

    Pittsburgh, Pennsylvania, 15236

  • Health Concepts

    Rapid City, South Dakota, 57702

  • Southern Cal Clinical Research

    Santa Ana, California, 92701

  • Piedmont Healthcare/Research

    Statesville, North Carolina, 28625

  • Cotton O'Neil Clinical Research Center

    Topeka, Kansas, 66606

  • Arcturus HC PLC Troy Med Res

    Troy, Michigan, 48098

  • Arcturus Healthcare, PLC

    Troy, Michigan, 48098

  • Hillcrest Family Health Center

    Waco, Texas, 76708

  • Chase Medical Research LLC

    Waterbury, Connecticut, 06708

Other trials in United States

Poland14 sites

  • Specderm Poznanska Sp. j.

    Bialystok, Podlaskie Voivodeship, 15-375

  • NZOZ Vita-Diabetica Malgorzata Buraczyk

    Bialystok, Podlaskie Voivodeship, 15-879

  • Specderm Poznańska Spółka Jawna

    Bialystok, 15-375

  • Med. Cent. Diabet. Endo. Metabol. DIAB-ENDO-MET

    Krakow, Lesser Poland Voivodeship, 31-261

  • Beata Miklaszewicz & Dariusz Dabrowski "CARDIAMED" s.j.

    Legnica, Lower Silesian Voivodeship, 59-220

  • Beata Mikłaszewicz & Dariusz Dąbrowski "CARDIAMED" s.j.

    Legnica, Lower Silesian Voivodeship, 59-220

  • Santa Sp. z o.o, Santa Familia Centrum Badan, Profilaktyki i Leczenia

    Lodz, Łódź Voivodeship, 90-302

  • EKAMED sp. z o.o.

    Lublin, Lublin Voivodeship, 20-718

  • EKAMED sp. z o.o.

    Lublin, 20-718

  • Formed 2 Sp. z o.o.

    Oświęcim, Lesser Poland Voivodeship, 32-600

  • Niepubliczny Zaklad Opieki Zdrowotnej Przychodnia Specjalistyczna A Wittek H Rudzki Sp. j.

    Ruda Śląska, Gornoslaskie, 41-709

  • Niepubliczny Zaklad Opieki Zdrowotnej Przychodnia Specjalistyczna A Wittek H Rudzki Sp. j.

    Ruda Śląska, 41-709

  • ETG Siedlce

    Siedlce, Masovian Voivodeship, 08-110

  • PANSTWOWY INSTYTUT MEDYCZNY MSWiA

    Warsaw, 02-507

Other trials in Poland

Bulgaria12 sites

  • Individual Practice For Specialized Outpatient Medical Care Doctor Miglena Rizova Ltd.

    Kyustendil, 2500

  • IPSOMC Dr. Miglena Rizova Ltd.

    Kyustendil, 2500

  • UMHAT "Kaspela", Depart. Endocrinology and Metab. Diseases

    Plovdiv, 4001

  • UMHAT Kaspela EOOD, Endocrinology and Metabolic Diseases Clinic

    Plovdiv, 4001

  • DCC Sveti Georgi EOOD

    Plovdiv, 4002

  • Diagnostic-Consultative Centre "Sveti Georgi" Eood

    Plovdiv, 4002

  • Medical centre Regina Life Clinic EOOD

    Sofia, 1000

  • UMHAT "Aleksandrovska"

    Sofia, 1431

  • UMHAT Aleksandrovska EAD, Densitometry and Bone Metabolic Diseases

    Sofia, 1431

  • USHATE "Akad. Ivan Penchev" Second Clinic of Endocrinology

    Sofia, 1431

  • USHATE Akad. Ivan Penchev EAD, Second Clinic of Endocrinology

    Sofia, 1431

  • AIPSMC Dr. Artin Magardichyan EOOD

    Varna, 9020

Other trials in Bulgaria

Japan12 sites

  • TOSAKI Clinic for Diabetes and Endocrinology_Diabetes and Endocrinology

    Aichi, 468-0009

  • Tokuyama clinic_Diabetic internal medicine

    Chiba, 261-0004

  • Tokuyama clinic

    Chiba, 261-0004

  • Akaicho Clinic

    Chiba-shi, Chiba, 260-0804

  • Naka Kinen Clinic_Internal medicine

    Ibaraki, 311-0113

  • Naka Kinen Clinic

    Ibaraki, 311-0113

  • Heiwadai Hospital_Internal Medicine

    Miyazaki, Miyazaki, 880-0034

  • Heiwadai Hospital

    Miyazaki, Miyazaki, 880-0034

  • Tokyo-Eki Center-building Clinic_Internal Medicine

    Tokyo, 103-0027

  • Tokyo-Eki Center-building Clinic

    Tokyo, 103-0027

  • Fukuwa Clinic_Internal Medicine

    Tokyo, 104-0031

  • Fukuwa Clinic

    Tokyo, 104-0031

Other trials in Japan

Croatia10 sites

  • Opca bolnica Karlovac

    Karlovac, 47000

  • Specijalna bolnica Krapinske Toplice - Endokrinologija

    Krapinske Toplice, 49217

  • Specijalna Bolnica za medicinsku rehabilitaciju Krapinske Toplice_Endocrinology

    Krapinske Toplice, 49217

  • Klinicki bolnicki centar Osijek_Endocrinology

    Osijek, 31 000

  • Klinicki bolnicki centar Osijek

    Osijek, 31 000

  • Clinical Hospital Centre Rijeka_Endocrinology

    Rijeka, Primorje-Gorski Kotar County, 51 000

  • KBC Rijeka, Endokrinologija

    Rijeka, Primorje-Gorski Kotar County, 51 000

  • Opca bolnica Varazdin_Endocrinology

    Varaždin, 42 000

  • Opca bolnica Varazdin

    Varaždin, 42 000

  • Poliklinika Solmed

    Zagreb, City of Zagreb, 10000

Other trials in Croatia

Romania10 sites

  • Mariodiab Clinic SRL

    Brasov, 500101

  • Institutul National De Diabet Nutritie Si Boli Metabolice Prof.Dr.N.Paulescu Bucuresti- Ion Movila

    Bucharest, Bucharest, 020475

  • Institutul National De Diabet Nutritie Si Boli Metabolice Prof.Dr.N.Paulescu Bucuresti- Ion Movila

    Bucharest, Bucurestii, 020475

  • Spitalul Clinic Judetean Urgenta Cluj-Napoca

    Cluj-Napoca, Cluj, 400006

  • SC Grand Med SRL

    Oradea, Bihor County, 410025

  • Grandmed SRL

    Oradea, Bihor County, 410159

  • Novus Medical Clinica SRL

    Ploieşti, Prahova, 100018

  • Sc Mediab Srl

    Târgu Mureş, Mureș County, 540142

  • Cabinet Medical Dr Geru SRL

    Timișoara, 300288

  • Spitalul Clinic Judetean De Urgenta Pius Brinzeu Timisoara

    Timișoara, 300723

Other trials in Romania

Spain10 sites

  • Complejo Hospitalario Universitario A Coruña

    A Coruña, 15006

  • Hospital Clinic i Provincial

    Barcelona, 08036

  • Hospital Vithas Sevilla

    Castilleja de la Cuesta, 41950

  • Hospital Gregorio Marañón

    Madrid, 28007

  • Complejo Hospitalario de Pontevedra - Hospital de Montecelo

    Pontevedra

  • Hospital Universitario Marqués de Valdecilla

    Santander, 39008

  • Clínica Nuevas Tecnologías en Diabetes y Endocrinología

    Seville, 41003

  • H. Infanta Luisa_Endocrino y Obesidad

    Seville, 41010

  • Hospital Infanta Luisa

    Seville, 41010

  • Hospital Nisa Sevilla Aljarafe

    Seville, 41950

Other trials in Spain

Greece9 sites

  • Iatriko Psychicou Private Clinic

    Athens, 115 25

  • U.G.H of Athens "Attikon"

    Athens, 12462

  • "Laiko" General Hospital of Athens

    Goudi/Athens, 11527

  • EUROMEDICA Gen Clinic The/ki, Endocrin,Metabolism,Diabetes

    Thessaloniki, 54645

  • 424 Military General Training Hospital - 2nd Department of Internal Medicine

    Thessaloniki, 564 29

  • 424 Military General Training Hospital

    Thessaloniki, 564 29

  • "Thermi" Private Hosital

    Thessaloniki, 57001

  • EUROMEDICA Gen Clinic The/ki, Endocrin,Metabolism,Diabetes

    Thessaloniki, GR-54643

  • "Thermi" Private Hosital

    Thessaloniki, GR-57001

Other trials in Greece

Hungary9 sites

  • Bajcsy-Zsilinszky Kórház

    Budapest, 1106

  • MH Egészségügyi Központ

    Budapest, 1134

  • Debreceni Egyetem

    Debrecen, Hajdú-Bihar, 4032

  • Debreceni Egyetem

    Debrecen, 4031

  • Debreceni Egyetem

    Debrecen, H-4031

  • Debreceni Egyetem

    Debrecen, H-4032

  • Békés Megyei Központi Kórház

    Gyula, 5700

  • Somogy Vármegyei Kaposi Mór Oktató Kórház

    Kaposvár, 7400

  • Somogy Vármegyei Kaposi Mór Oktató Kórház

    Kaposvár, H-7400

Other trials in Hungary

Germany7 sites

  • Zentrum fuer klinische Studien Suedbrandenburg GmbH

    Elsterwerda, 04910

  • Zentrum für klinische Studien Südbrandenburg GmbH

    Elsterwerda, 04910

  • InnoDiab Forschung GmbH

    Essen, 45136

  • Wendisch - Dahl Hamburg - DZHW

    Hamburg, 22607

  • Wendisch/Dahl Hamburg

    Hamburg, 22607

  • Institut für Diabetesforschung GmbH Münster - Dr. med. Rose

    Münster, 48145

  • RED-Institut für medizinische Forschung und Fortbildung GmbH

    Oldenburg in Holstein, 23758

Other trials in Germany

Slovakia5 sites

  • DENTAVIA s.r.o.

    Poprad, 05801

  • DIABETOL, s.r.o.

    Prešov, 080 01

  • OLIVER - MED s.r.o.

    Rimavská Sobota, 979 01

  • Peter Farkas MD, s.r.o.

    Šahy, Slovak Republic, 93601

  • MEDIVASA, s.r.o., Diabetologicka ambulancia

    Žilina, 010 01

Other trials in Slovakia

About this study

Official title: Safety and Efficacy of Once-weekly Subcutaneous and Once-daily Oral NNC0487-0111 in Participants With Type 2 Diabetes - a Dose Finding Study

The study will look at how well different doses of a new medicine called NNC0487-0111 help lower the blood sugar and body weight in people with type 2 diabetes. NNC0487-0111 is a new medicine which cannot be prescribed by doctors but has previously been tested in humans. Participants will either get NNC0487-0111, which is given as tablets or as injections, or placebo. Which treatment the participant get is decided by chance.The study will last for about 43 weeks.

Being tested
NNC0487-0111 subcutanous, Placebo (NNC0487-0111 subcutanous), NNC0487-0111 oral, Placebo (NNC0487-0111 oral)
Medical subject headings
Diabetes Mellitus, Type 2

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • NNC0487-0111 subcutanousDrug

    NNC0487-0111 administered subcutanously (under the skin)

  • Placebo (NNC0487-0111 subcutanous)Drug

    NNC0487-0111 placebo administered subcutanously (under the skin)

  • NNC0487-0111 oralDrug

    NNC0487-0111 administered orally (in the mouth)

  • Placebo (NNC0487-0111 oral)Drug

    NNC0487-0111 placebo administered orally (in the mouth)

Study groups in NCT06542874
Study groupRoleWhat they receive
Placebo subcutaneousPlacebo comparatorPlacebo for subcutaneous treatment
Receives: Drug: Placebo (NNC0487-0111 subcutanous)
NNC0487-0111 subcutaneous dose 1ExperimentalNNC0487-0111 subcutaneous dose 1 treatment
Receives: Drug: NNC0487-0111 subcutanous
NNC0487-0111 subcutaneous dose 2ExperimentalNNC0487-0111 subcutaneous dose 2 treatment
Receives: Drug: NNC0487-0111 subcutanous
NNC0487-0111 subcutaneous dose 3ExperimentalNNC0487-0111 subcutaneous dose 3 treatment
Receives: Drug: NNC0487-0111 subcutanous
NNC0487-0111 subcutaneous dose 4ExperimentalNNC0487-0111 subcutaneous dose 4 treatment
Receives: Drug: NNC0487-0111 subcutanous
NNC0487-0111 subcutaneous dose 5ExperimentalNNC0487-0111 subcutaneous dose 5 treatment
Receives: Drug: NNC0487-0111 subcutanous
NNC0487-0111 subcutaneous dose 6ExperimentalNNC0487-0111 subcutaneous dose 6 treatment
Receives: Drug: NNC0487-0111 subcutanous
Placebo oralPlacebo comparatorPlacebo for oral treatment
Receives: Drug: Placebo (NNC0487-0111 oral)
NNC0487-0111 oral dose 1ExperimentalNNC0487-0111 oral dose 1 treatment
Receives: Drug: NNC0487-0111 oral
NNC0487-0111 oral dose 2ExperimentalNNC0487-0111 oral dose 2 treatment
Receives: Drug: NNC0487-0111 oral
NNC0487-0111 oral dose 3ExperimentalNNC0487-0111 oral dose 3 treatment
Receives: Drug: NNC0487-0111 oral

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Change in HbA1c

    percent point

    Measured: From baseline (week 0) to end of treatment (week 36)

Secondary outcomes (17)

  1. Relative change in body weight

    percent

    Measured: From baseline (week 0) to end of treatment (week 36)

  2. Change in body weight

    kg

    Measured: From baseline (week 0) to end of treatment (week 36)

  3. Change in fasting plasma glucose (FPG)

    mmol/L

    Measured: From baseline (week 0) to end of treatment (week 36)

  4. CGM: Change in time in range (TIR) 3.9-10.0 mmol/L (70-180 mg/dL)

    percent points

    Measured: From baseline (week 0) to end of treatment (week 36)

  5. Change in body mass index (BMI)

    kg/m^2

    Measured: From baseline (week 0) to end of treatment (week 36)

  6. Change in waist circumference

    cm

    Measured: From baseline (week 0) to end of treatment (week 36)

  7. Change in systolic blood pressure (SBP)

    mmHg

    Measured: From baseline (week 0) to end of treatment (week 36)

  8. Change in average 24-hour systolic blood pressure (SBP)

    mmHg

    Measured: From baseline (week 0) to end of treatment (week 36)

  9. Change in high sensitivity C-Reactive Protein (hsCRP)

    Ratio to baseline

    Measured: From baseline (week 0) to end of treatment (week 36)

  10. Change in total cholesterol

    Ratio to baseline

    Measured: From baseline (week 0) to end of treatment (week 36)

  11. Change in high-density lipoprotein (HDL) cholesterol

    Ratio to baseline

    Measured: From baseline (week 0) to end of treatment (week 36)

  12. Change in low-density lipoprotein (LDL) cholesterol

    Ratio to baseline

    Measured: From baseline (week 0) to end of treatment (week 36)

  13. Change in triglycerides

    Ratio to baseline

    Measured: From baseline (week 0) to end of treatment (week 36)

  14. Number of adverse events

    Count of events

    Measured: From baseline (week 0) to end of study (week 40)

  15. Change in Urinary Albumin/Creatinine Ratio (UACR)

    Ratio to baseline

    Measured: From baseline (week 0) to end of treatment (week 36)

  16. Participant without macroalbuminuria (UACR < 300 mg/g) at baseline (week 0) developing (yes/no) new onset of macroalbuminuria (UACR ≥ 300 mg/g)

    Count of participant

    Measured: At end of treatment (week 36)

  17. Change in eGFR creatinine- and cystatin C based CKD-EPI

    mL/min/1.73 m^2

    Measured: From baseline (week 0) to end of treatment (week 36)

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted7 Aug 2024
  2. Study start7 Aug 2024
  3. Primary completion1 Oct 2025
  4. Study completion24 Oct 2025

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomised
Intervention model
Parallel groups
Masking
Quadruple blind
Who is masked
Participant, Care provider, Investigator, Outcomes assessor
Enrolment
448 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT06542874
Sponsor's protocol ID
NN9490-7678
Other IDs
U1111-1296-9708, 2023-509412-28, 2023
Status last verified
Sep 2026
First submitted
5 Aug 2024
Last updated
2 Oct 2026
Results posted
No
Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
Individual data sharing
Yes: According to the Novo Nordisk disclosure commitment on novonordisk-trials.com

Publications

  • Mora P, Aroda VR, Asong M, Bluher M, Heftdal LD, Carlander AF, Vilsen LN, Rosenstock J. Efficacy and safety of once-weekly subcutaneous zenagamtide, a novel unimolecular GLP-1 and amylin receptor agonist, in type 2 diabetes: a multicentre, randomised, parallel, double-blind, placebo-controlled, dose-finding, phase 2 trial. Lancet. 2026 Jul 30:S0140-6736(26)01248-1. doi: 10.1016/S0140-6736(26)01248-1. Online ahead of print.

    PubMed 42532080

  • Mora P, Aroda VR, Asong M, Bluher M, Carlander AF, Kaltoft M, Vilsen LN, Rosenstock J. Efficacy and safety of once-daily oral zenagamtide, a novel unimolecular GLP-1 and amylin receptor agonist, in adults with type 2 diabetes: a multicentre, randomised, parallel, double-blind, placebo-controlled, dose-finding, phase 2 trial. Lancet. 2026 Jul 30:S0140-6736(26)01247-X. doi: 10.1016/S0140-6736(26)01247-X. Online ahead of print.

    PubMed 42532079

Questions about this trial

What is this clinical trial studying?

A Phase 2 study testing NNC0487-0111 subcutanous and NNC0487-0111 oral in people with Type 2 Diabetes (T2D), run by Novo Nordisk A/S at 137 sites in 11 countries.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 6 inclusion and 3 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 2 Oct 2026. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 137 sites in United States, Poland, Bulgaria, Japan, Croatia and 6 more countries. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

What does this phase mean?

Phase 2 studies give the treatment to a larger group to see whether it has the intended effect and to keep checking safety.

Not every study follows the same path, and some studies (observational studies, device studies) have no phase.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Change in HbA1c (time frame: From baseline (week 0) to end of treatment (week 36)). It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT06542874, which also lists 2 linked publications.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 2 Oct 2026.

AzTrials uses cookies for analytics and advertising. You can accept or reject them; the site works either way. Privacy Policy.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in